Codiak Biosciences logo — company profile

Codiak Biosciences

Founded 2015 Post Ipo Equity Total: $257.40M Biotechnology, Health and Wellness

General Information

Company Name Codiak Biosciences
Founded Year 2015
Founders / Decision Makers
Team member
Industries Biotechnology, Health and Wellness
Funding Stage Post Ipo Equity
Social

Get notified when Codiak Biosciences moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Codiak Biosciences

Codiak Biosciences is a biotechnology startup that was founded in 2015. The company is focused on developing exosome-based therapeutics, which constitute a new class of medicines with the potential to address a wide spectrum of diseases with high unmet medical need. Codiak leverages the biology of exosomes as natural intercellular transfer mechanisms and has created its proprietary engEx Platform to enhance the innate properties of exosomes. This platform enables the design, engineering, and manufacture of novel exosome therapeutic candidates. Codiak has built a robust pipeline of engineered exosomes aimed at treating a broad range of disease areas, including oncology, neuro-oncology, neurology, neuromuscular disease, and infectious disease. The startup has recently secured a significant $20.00MPost-IPO Equity investment on 12 September 2022. This funding is indicative of the growing interest in the potential of exosome-based therapeutics and bodes well for Codiak's future development and product commercialization efforts. As Codiak continues to advance its innovative therapies, it positions itself as a promising player in advancing treatments for various challenging diseases within the biopharmaceutical industry.

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 12 Sep 2022
Post-IPO Equity •••••• 1
Investor
05 Jul 2022
Post-IPO Equity •••••• - 11 Feb 2021
Series C •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
29 Nov 2017
Series B •••••• 6
Investor Investor Investor Investor Investor
•••• ••••
26 Jan 2016

View All 6 Funding Rounds

Codiak Biosciences Alternatives & Competitors

Codiak Biosciences vs

Pioneering impactful biotechnology and advanced healthcare services through innovative platforms lik...

Post Ipo Equity
4 employees
Biopharma, Biotechnology
Codiak Biosciences vs
Exopharm Ltd
Exopharm Ltd Australia

Delivering Transformative Medicines

5 employees
Biopharma, Biotechnology
Codiak Biosciences vs

ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and gu...

Series C
103 employees
Biotechnology, Health Care

FAQ About Codiak Biosciences

Codiak is a clinical-stage biopharmaceutical company focused on developing exosome-based therapeutics, a new class of medicines with the potential to address a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms,...
Codiak Biosciences was founded in 2015.
Codiak Biosciences operates in the following industries: Biotechnology, Health and Wellness.
Codiak Biosciences has completed 6 funding rounds, raising a total of $257.40M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Codiak Biosciences include Avalon Globocare Corp (NASDAQ: ALBT), Exopharm Ltd, Exosome Diagnostics, a Bio-Techne brand, ReNeuron Group Plc, Mantra Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Codiak Biosciences and Avalon Globocare Corp (NASDAQ: ALBT) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Codiak Biosciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy